AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus

Journal of Virology

Volumn 87, Issue 2, 2013, Pages 746-755

  Kondratowicz, Andrew S ^a,d   Hunt, Catherine L ^a   Davey, Robert A ^b   Cherry, Sara ^c   Maury, Wendy J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 2; PHOSPHOTRANSFERASE INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE GENE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LASSA VIRUS; MACROPHAGE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL LINE; VERO CELL; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ENTRY; VIRUS GENE; VIRUS INFECTIVITY; VIRUS REPLICATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; EBOLAVIRUS; ENZYME INHIBITORS; HUMANS; MACROPHAGES; PINOCYTOSIS; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION;

EBOLA VIRUS; LASSA VIRUS; MARBURGVIRUS; ZAIRE EBOLAVIRUS;

EID: 84871988914     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01634-12     Document Type: Article

References (91)

1. Feldmann H, Geisbert TW. 2011. Ebola haemorrhagic fever. Lancet 377:849-862.
2. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76:6841-6844.
3. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. 2012. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 86:364-372.
4. Brindley MA, Hughes L, Ruiz A, McCray PB, Jr, Sanchez A, Sanders DA, Maury W. 2007. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J. Virol. 81:7702-7709.
5. Carette JE, Raaben M, Wong AC, Herbert AS, Obermosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AP, Ruther G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Neimann Pick C1. Nature 477: 340-343.
6. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal that Neimann-Pick C1 is essential for Ebolavirus entry. Nature 477: 344-348.
7. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, Kuhn JH, White JM. 2009. The primed Ebolavirus glycoprotein (19- kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 83:2883-2891.
8. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB, Jr, Chiorini J, Maury W. 2011. From the Cover: T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburg virus. Proc. Natl. Acad. Sci. U. S. A. 108:8426-8431.
9. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, Pohlmann S. 2003. DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115-123.
10. Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, Kobasa D, Feldmann H, Irimura T, Kawaoka Y. 2004. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78:2943-2947.
11. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. 1997. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 94:14764-14769.
12. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. 2000. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74:10194-10201.
13. Lasala F, Arce E, Otero JR, Rojo J, Delgado R. 2003. Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans. Antimicrob. Agents Chemother. 47:3970-3972.
14. Marzi A, Gramberg T, Simmons G, Moller P, Rennekamp AJ, Krumbiegel M, Geier M, Eisemann J, Turza N, Saunier B, Steinkasserer A, Becker S, Bates P, Hofmann H, Pohlmann S. 2004. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 78: 12090-12095.
15. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645.
16. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80:4174-4178.
17. Miller E, Obernosterer G, Raaben M, Herbert A, Deffieu M, Krishnan A, Ndungo E, Sandesara R, Carette J, Kuehne A, Ruthel G, Pfeffer S, Dye J, Whelan S, Brummelkamp T, Chandran K. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 31:1947-1960.
18. Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, Aman MJ, Hope TJ. 2010. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology 401:18-28.
19. Empig CJ, Goldsmith MA. 2002. Association of the caveola vesicular system with cellular entry by filoviruses. J. Virol. 76:5266-5270.
20. Hunt CL, Kolokoltsov AA, Davey RA, Maury W. 2011. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire Ebolavirus. J. Virol. 85:334-347.
21. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y. 2010. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6:e1001121. doi:10.1371/journal.ppat.1001121.
22. Quinn K, Brindley MA, Weller ML, Kaludov N, Kondratowicz A, Hunt CL, Sinn PL, McCray PB, Jr, Stein CS, Davidson BL, Flick R, Mandell R, Staplin W, Maury W, Chiorini JA. 2009. Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J. Virol. 83:10176-10186.
23. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. 2010. Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6:e1001110. doi:10.1371/journal.ppat.1001110.
24. Sanchez A. 2007. Analysis of filovirus entry into Vero E6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity. J. Infect. Dis. 196(Suppl. 2):S251-S258.
25. Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T, Feldmann H, Schnittler HJ. 2011. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204(Suppl 3):S957-S967.
26. Mulherkar N, Raaben M, de la Torre JC, Whelan SP, Chandran K. 2011. The Ebola virus glycoprotein mediates entry via a non-classical dynamindependent macropinocytic pathway. Virology 419:72-83.
27. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. 2008. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog. 4:e1000141. doi:10.1371/journal.ppat.1000141.
28. Fulco M, Sartorelli V. 2008. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 7:3669-3679.
29. Ghillebert R, Swinnen E, Wen J, Vandesteene L, Ramon M, Norga K, Rolland F, Winderickx J. 2011. The AMPK/SNF1/SnRK1 fuel gauge and energy regulator: structure, function and regulation. FEBS J. 278:3978-3990.
30. Hardie DG. 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25:1895-1908.
31. Mankouri J, Harris M. 2011. Viruses and the fuel sensor: the emerging link between AMPK and virus replication. Rev. Med. Virol. 21:205-212.
32. Carling D. 2004. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 29:18-24.
33. Hardie DG. 2007. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8:774-785.
34. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, Haire LF, Saiu P, Howell SA, Aasland R, Martin SR, Carling D, Gamblin SJ. 2011. Structure of mammalian AMPK and its regulation by ADP. Nature 472:230-233.
35. Williams T, Brenman JE. 2008. LKB1 and AMPK in cell polarity and division. Trends Cell Biol. 18:193-198.
36. Bae HB, Zmijewski JW, Deshane JS, Tadie JM, Chaplin DD, Takashima S, Abraham E. 2011. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 25:4358-4368.
37. Blume C, Benz PM, Walter U, Ha J, Kemp BE, Renne T. 2007. AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J. Biol. Chem. 282:4601-4612.
38. Guest CB, Chakour KS, Freund GG. 2008. Macropinocytosis is decreased in diabetic mouse macrophages and is regulated by AMPK. BMC Immunol. 9:42. doi:10.1186/1471-2172-9-42.
39. Moser TS, Jones RG, Thompson CB, Coyne CB, Cherry S. 2010. A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog. 6:e1000954. doi: 10.1371/journal.ppat.1000954.
40. Thomson DM, Ascione MP, Grange J, Nelson C, Hansen MD. 2011. Phosphorylation of VASP by AMPK alters actin binding and occurs at a novel site. Biochem. Biophys. Res. Commun. 414:215-219.
41. Maury W. 1994. Monocyte maturation controls expression of equine infectious anemia virus. J. Virol. 68:6270-6279.
42. Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I. 2009. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther. 16:44-52.
43. Gao Y, Whitaker-Dowling P, Watkins SC, Griffin JA, Bergman I. 2006. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J. Virol. 80:8603-8612.
44. Jeffers SA, Sanders DA, Sanchez A. 2002. Covalent modifications of the Ebola virus glycoprotein. J. Virol. 76:12463-12472.
45. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886-889.
46. Mackett M, Smith GL, Moss B. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
47. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9:1306-1312.
48. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. 2010. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 16:662-664.
49. Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, McCray PB, Jr, Quinn K, Weller ML, Chiorini JA, Maury W. 2011. Tyrosine kinase receptor Axl enhances entry of Zaire Ebolavirus without direct interactions with the viral glycoprotein. Virology 415:83-94.
50. Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, Spear GT. 2005. Mannosebinding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complementmediated virus neutralization. J. Gen. Virol. 86:2535-2542.
51. Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW. 2003. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DCSIGNR. J. Virol. 77:1337-1346.
52. 1-Integrin controls Ebolavirus entry by regulating endosomal cathepsins. Proc. Natl. Acad. Sci. U. S. A. 106:8003-8008.
53. Shimojima M, Ikeda Y, Kawaoka Y. 2007. The mechanism of Axlmediated Ebola virus infection. J. Infect. Dis. 196(Suppl. 2):S259-S263.
54. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S, Feldmann H, Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80:10109-10116.
55. 1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20-26.
56. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174.
57. Moser TS, Schieffer D, Cherry S. 2012. AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis. PLoS Pathog. 8:e1002661. doi:10.1371/journal.ppat.1002661.
58. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179(Suppl 1):S203-S217.
59. Geisbert TW, Jaax NK. 1998. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct. Pathol. 22:3-17.
60. Johnson E, Jaax N, White J, Jahrling P. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-236.
61. Ryabchikova EI, Kolesnikova LV, Luchko SV. 1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179(Suppl 1):S199-S202.
62. Schnittler HJ, Feldmann H. 1998. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin. Infect. Dis. 27:404-406.
63. Wyers M, Formenty P, Cherel Y, Guigand L, Fernandez B, Boesch C, Le Guenno B. 1999. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. J. Infect. Dis. 179(Suppl. 1):S54-S59.
64. Jorgensen SB, Viollet B, Andreelli F, Frosig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF. 2004. Knockout of the α2 but not α1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contractioninduced glucose uptake in skeletal muscle. J. Biol. Chem. 279:1070-1079.
65. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B. 2006. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell. Biol. 26:5336-5347.
66. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. 2003. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111:91-98.
67. Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320:531-535.
68. Mercer J, Helenius A. 2009. Virus entry by macropinocytosis. Nat. Cell Biol. 11:510-520.
69. West MA, Bretscher MS, Watts C. 1989. Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J. Cell Biol. 109:2731-2739.
70. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. 2010. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J. Virol. 84:163-175.
71. Mercer J, Schelhaas M, Helenius A. 2010. Virus entry by endocytosis. Annu. Rev. Biochem. 79:803-833.
72. Schelhaas M. 2010. Come in and take your coat off: how host cells provide endocytosis for virus entry. Cell. Microbiol. 12:1378-1388.
73. Kerr MC, Teasdale RD. 2009. Defining macropinocytosis. Traffic 10: 364-371.
74. de Vries E, Tscherne DM, Wienholts MJ, Cobos-Jimenez V, Scholte F, Garcia-Sastre A, Rottier PJ, de Haan CA 2011. Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog. 7:e1001329. doi:10.1371/journal.ppat.1001329.
75. Sanchez EG, Quintas A, Perez-Nunez D, Nogal M, Barroso S, Carrascosa AL, Revilla Y. 2012. African swine fever virus uses macropinocytosis to enter host cells. PLoS Pathog. 8:e1002754. doi:10.1371/journal.ppat.1002754.
76. Mercer J, Knebel S, Schmidt FI, Crouse J, Burkard C, Helenius A. 2010. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc. Natl. Acad. Sci. U. S. A. 107:9346-9351.
77. Schmidt FI, Bleck CK, Helenius A, Mercer J. 2011. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 30:3647-3661.
78. Amato S, Liu X, Zheng B, Cantley L, Rakic P, Man HY. 2011. AMPactivated protein kinase regulates neuronal polarization by interfering with PI 3-kinase localization. Science 332:247-251.
79. Araki N, Hatae T, Furukawa A, Swanson JA. 2003. Phosphoinositide-3-kinase-independent contractile activities associated with Fcα-receptormediated phagocytosis and macropinocytosis in macrophages. J. Cell Sci. 116:247-257.
80. Araki N, Johnson MT, Swanson JA. 1996. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J. Cell Biol. 135:1249-1260.
81. Horman S, Morel N, Vertommen D, Hussain N, Neumann D, Beauloye C, El Najjar N, Forcet C, Viollet B, Walsh MP, Hue L, Rider MH. 2008. AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. J. Biol. Chem. 283:18505-18512.
82. Swanson JA, Johnson MT, Beningo K, Post P, Mooseker M, Araki N. 1999. A contractile activity that closes phagosomes in macrophages. J. Cell Sci. 112:307-316.
83. Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, Schuh K, Gertler F, Munzel T, Renne T. 2009. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J. Cell Sci. 122:3954-3965.
84. Barzik M, Kotova TI, Higgs HN, Hazelwood L, Hanein D, Gertler FB, Schafer DA. 2005. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J. Biol. Chem. 280:28653-28662.
85. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. 2003. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu. Rev. Cell Dev. Biol. 19:541-564.
86. Mejillano MR, Kojima S, Applewhite DA, Gertler FB, Svitkina TM, Borisy GG. 2004. Lamellipodial versus filopodial mode of the actin nanomachinery: pivotal role of the filament barbed end. Cell 118:363-373.
87. Ridley AJ. 2011. Life at the leading edge. Cell 145:1012-1022.
88. Bear JE, Gertler FB. 2009. Ena/VASP: towards resolving a pointed controversy at the barbed end. J. Cell Sci. 122:1947-1953.
89. Bear JE, Loureiro JJ, Libova I, Fassler R, Wehland J, Gertler FB. 2000. Negative regulation of fibroblast motility by Ena/VASP proteins. Cell 101: 717-728.
90. Chesarone MA, Goode BL. 2009. Actin nucleation and elongation factors: mechanisms and interplay. Curr. Opin. Cell Biol. 21:28-37.
91. Howe AK, Hogan BP, Juliano RL. 2002. Regulation of vasodilatorstimulated phosphoprotein phosphorylation and interaction with Abl by protein kinase A and cell adhesion. J. Biol. Chem. 277:38121-38126.